Feola S, Russo S, Martins B, Lopes A, Vandermeulen G, Flühler V, et al. Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine. Front Immunol. 2022;13:826164 pubmed publisher

Meyers L, Gutiérrez A, Boyle C, Terry F, McGonnigal B, Salazar A, et al. Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. NPJ Vaccines. 2021;6:71 pubmed publisher

Dobrica M, Lazar C, Paruch L, Skomedal H, Steen H, Haugslien S, et al. A novel chimeric Hepatitis B virus S/preS1 antigen produced in mammalian and plant cells elicits stronger humoral and cellular immune response than the standard vaccine-constituent, S protein. Antiviral Res. 2017;144:256-265 pubmed publisher

Torcellan T, Hampton H, Bailey J, Tomura M, Brink R, Chtanova T. In vivo photolabeling of tumor-infiltrating cells reveals highly regulated egress of T-cell subsets from tumors. Proc Natl Acad Sci U S A. 2017;114:5677-5682 pubmed publisher

Stavaru C, Onu A, Lupulescu E, Tucureanu C, Raşid O, Vlase E, et al. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: Preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Hum Vaccin Immunother. 2016;12:1009-26 pubmed publisher